We are live on !
Find out more
Prosight Management Portfolio holdings
AUM
$515M
Turnover
48.89%
1-Year Est. Return
2.95%
This Fund
S&P 500
This Quarter Est. Return
+6.58%
1 Year Est. Return
-2.95%
3 Year Est. Return
+53.41%
5 Year Est. Return
-10.05%
10 Year Est. Return
–
AUM
$160M
AUM Growth
+$37.8M
(+31%)
Cap. Flow
+$30.7M
Cap. Flow % of AUM
Cap. Flow %
19.19%
Top 10 Holdings %
Top 10 Hldgs %
54.86%
Holding
54
New
17
Increased
15
Reduced
14
Closed
8
Avg Time Held
Equity + Options
0.6
years
Top 10 Avg Time Held
Equity + Options
0.6
years
Top 20 Avg Time Held
Equity + Options
0.8
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$9.48M |
| 2 |
Exicure
XCUR
|
+$5.81M |
| 3 |
CNVY
Convey Health Solutions Holdings
CNVY
|
+$4.75M |
| 4 |
KalVista Pharmaceuticals
KALV
|
+$4.74M |
| 5 |
R1 RCM
RCM
|
+$4.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$6.04M |
| 2 |
Prothena
PRTA
|
+$5.55M |
| 3 |
Aurinia Pharmaceuticals
AUPH
|
+$2.94M |
| 4 |
Inovalon Holdings
INOV
|
+$2.45M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$2.35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.1% |
| 2 | Industrials | 2.39% |
| 3 | Miscellaneous | 1.27% |
| 4 | Energy | 1.24% |
Similar funds
LHC
Prosight Management's Q2 2021 Portfolio in Review
As of Q2 2021, Prosight Management held 54 positions worth $160M, up 31% from $122M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Prosight Management deployed $30.7M of net new capital in Q2 2021, opening 17 new positions and adding to 15 existing holdings. Its largest new stake was Haemonetics: 134,000 shares worth $8.93M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier, followed by Industrials and Miscellaneous.
On the sell side, the largest reduction was Prothena, an estimated $5.55M trimmed.
- Prosight Management's largest Q2 2021 buy was Haemonetics: 134,000 shares worth $8.93M.
- Prosight Management added most to Exicure in Q2 2021, an estimated $5.81M increase.
- Prosight Management's biggest Q2 2021 reduction was Prothena, cutting an estimated $5.55M.
- Prosight Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $6.04M.
- Prosight Management's ten largest holdings make up 55% of its $160M portfolio in Q2 2021.
- Prosight Management opened 17 new positions and closed 8 in Q2 2021.
- Prosight Management's portfolio value rose 31% quarter-over-quarter to $160M.
Based on Prosight Management's 13F filing for Q2 2021, filed 13 Aug 2021.